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Question of correct choice of the first therapeutical 
activity in differentiated thyroid cancer after thyroidec-
tomy is still under discussion. The decisions are often 
based on empirical approach. Several factors, such as 
thyroid remnants volume, the number and the size of 
pathological sites accumulating radioiodine, histology 
of the tumor may be taken into account in the choice of 
the activity value [1, 5].  Nevertheless the factors as-
sociated with ablation failure are not fully understood. 
In particular, it is not certain whether the use of activi-
ties higher than 3.7 GBq would result in any additional 
benefit [7]. Meanwhile several researches have been 
yet focused on the use of low activities for ablating 
the thyroid remnants upon thyroidectomy. Even the 
possibility of low activities fractionation by successive 
treatment courses is still discussed [6]. Standardized 
regimens of 131I therapy in fact have several advantages 
over the attempts of individual selection of the activi-
ties based on accounting preliminary kinetics data [14, 
15]. Either administering an empirically chosen fixed 
dose or using dosimetry — guided techniques, can 
achieve remnants ablation. Because of the technical 
and logistic difficulties, most centers have adapted the 
fixed dose or standard–dose technique for remnants 
ablation using 131I [2]. In [8] the individual activity value 
A0 was calculated for the cases without metastatic le-
sions and when only thyroid remnants were present. 
A0 could be estimated based on the kinetics of 
131I 
distribution assessed in diagnostic scintigraphy. As a 
rule, in the case of metastases in lymph nodes revealed 
in diagnostic scintigraphy the therapeutical activities 
amounted approximately to 3600 MBq [13]. Neverthe-
less, the relative contribution of thyroid remnants size 
to the outcome of the first course of radioiodine treat-
ment has not been yet established. It has not been also 
established which factors are more decisive in terms of 
the influence on treatment outcome, namely the first 
activity administered or thyroid remnants volume and 
the number and the size of metastatic lymph nodes.
The aim of the study was to estimate the relative 
contribution of the first activity to the outcome of the 
first course of radioiodine treatment as compared with 
other variables such as remnants volume, size and the 
number of metastases in lymph nodes.
Patients and methods  
68 adult patients (aged from 46 to 76, 55 ± 7 in aver-
age) with differentiated thyroid cancer have been treated 
with radioiodine after thyroidectomy. Patients have been 
operated in different clinics in Ukraine. In every patient 
the scope of the surgery comprised resection of regional 
lymph nodes with possible metastases. Nevertheless, 
only patients with metastases in lymph nodes accumulat-
ing radioiodine have been enrolled into the study.  
15 patients had follicular thyroid cancer, 40 — papil-
lary, 12 — mixed form, in one patient histological data 
were not available. Therapeutical activities amounted 
from 1000 to 6000 MBq. From 1 to 4 courses of ra-
dioiodine treatment were necessary for total thyroid 
tissue ablation. If the first course failed, the following 
successive courses were appointed. 55 patients had 
full ablation of metastases and remnants after the first 
course of the treatment. The following parameters of 131I 
kinetics in remnants and lymph nodes were measured 
in 25 random patients from the first day of treatment 
activity administration: the effective half- life in remnants 
and pathological lymph nodes and level of radioiodine 
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accumulation in remnants in 24 h after activity admin-
istration. Calculations were made on gamma camera 
6400 (Hungary) and SPECT E. Cam (Siemens).
Regression analysis has been applied for estimating 
the relative contribution of the first activity to the outcome 
of the first course of radioiodine treatment as compared 
with individual peculiarities of the patient such as thyroid 
remnants volume, number of lymph nodes metastases 
and histological type of the tumor. Logistic function was 
used in regression analysis for describing the probability 
of full metastases ablation after the first course.
ResULts 
For evaluating the relative contribution of the first 
activity on the outcome of the first course, the whole 
interval of the activities administered was divided in 
1000 MBq subintervals. In every subinterval p has 
been calculated as the ratio of the number of patients 
with full thyroid tissue ablation after the first course 
of the treatment to the total number of patients being 
treated in such activity interval. p value as a function 
of activity is plotted in Fig. 1.
Fig. 1. p as a function of the first activity value A. The number 
of patients being treated in every activity 131I interval is indicated 
in brackets. 
From Fig. 1 it is obvious that the probability of full 
ablation of metastases and remnants increases with 
increasing value of the first activity. The relationship 
is approximated by linear function. p does not take 
the zero value throughout all the range of activities 
administered even in the lowest activity of 1100 MBq. 
This fact suggests that individual values of the optimal 
activity for each patient do exist. 
p = 1 in the activity interval from 5000 MBq to 
6000 MBq. The plotted function reflects the overall p 
increment with the increasing activity, not taking into 
account the individual features of each patient. 
The total number of patients required one or more 
than one courses for complete ablation of remnants 
and metastases for every histology group is indicated 
in Table 1.
Table 1. The number of patients treated with 1 or > 1 courses in different 
histology groups
Total number of courses Papillary cancer Follicular cancer Mixed form
1 33 11 11
> 1 7 4 1
From Table 1 it could be seen that the relative 
percentage of cases requiring more than 1 course, 
seems to be the same whatever the histological type 
of thyroid cancer. 
For comparing the strength of the influence of param-
eters of radioiodine distribution in thyroid remnants and 
metastases on treatment outcome the regression analy-
sis has been applied in 25 randomly selected patients. 
Parameters of radioiodine distribution in thyroid tis-
sue were as follows: average value of the first treatment 
activity Aav = 3631 MBq; effective half-time of radioiodine 
excretion in remnants Tav = 3.28 days; level of thyroid rem-
nants accumulation relative to its background value in 24 
h after activity administration σav = 25.68. In metastases in 
lymph nodes average value in 24 h after beginning of the 
treatment σlnav = 12.06 (from 0.6 to 54). Effective half-life 
of 131I excretion in lymph nodes in average was equal 2.7 + 
1.6 days (from 0.5 days to 6.19 days). 
In 17 of 25 patients remnants and metastases were 
completely ablated after the first course of the treat-
ment. 8 patients were subjected to several courses of 
radioiodine treatment.
In principle, the radioiodine therapy outcome may 
be reduced to two discrete values — 1 or 0 (ablation 
success or failure). Nevertheless, the outcome depends 
on several continuous parameters such as therapeutic 
activity, parameters of radioiodine distribution in thyroid 
tissue and other factors. All of them may be aligned in 
certain hierarchy depending on the strength of their 
influence on the outcome of the first course of the treat-
ment. We have attempted to isolate those factors which 
are decisive ones and to clear up whether it is possible 
to indicate such activity value which could overcome the 
effects of individual factors such as the number and the 
size of metastatic lesions in lymph nodes.
Logistic function depending on measured param-
eters of radioiodine distribution in thyroid tissue was 
chosen as treatment outcome function of the first 
course. This function has two asymptotic values which 
were assigned as 1 — related to full metastases and 
remnants ablation after the first course or 0 — in case 
of the necessity of several courses of radioiodine treat-
ment (the failure of the first course).
The normalization of the parameters to the average 
values allows us to compare their relative contribution 
to the treatment outcome:
An = A / Aav; σn = σ / σav
After the normalization of the parameters included 
into calculations, the function f of treatment outcome 
was determined (Statistics 5.5):
f = exp (-3.2 + 4.46 ⋅ Аn – 0.29 ⋅ σn ) / [1 + exp (-3.2 + 
4.46 ⋅ Аn – 0.29 ⋅ σn )] (1)
р = 0.04.
f was equal 0.76 + 0.18 in patients with total thyroid 
tissue ablation after the first course of the treatment;
and f = 0.50 + 0.16 in the case of the necessity of 
the several courses (upon failure of one course). 
Fig. 2 shows the fraction of patients with the total 
thyroid tissue ablation after the first course in the every 
activity interval and f value for 25 randomly selected 
patients under study. f was calculated on the basis 
of equation (1); the mean value of σ for the patients 
treated in this activity interval and average activity value 
have been used in the calculations. 
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Fig. 2. The actual fraction of patients with total thyroid tissue 
ablation as compared with calculated f values in the treatment 
activity interval. The number of patients in every activity interval 
is indicated in the brackets
It could be seen that calculated f values coincide 
with the fraction of the patients treated with not more 
then one course with the high accuracy.  
From the equation (1) it could be concluded that the 
greater is remnants volume reflecting in σ, the greater 
treatment activity is necessary for increasing the prob-
ability of the treatment outcome after the first course 
(negative σn term of equation — 0.29). It should also 
bear in mind that σ reflects indirectly also the functional 
activity of thyroid remnants.  According to our data % of 
radioiodine accumulation in remnants in 24 hours after 
activity administration correlates highly with σ (k = 0.8). 
Activity value has the decisive influence on the treat-
ment outcome as compared with σ (4.46 vs 0.29). Includ-
ing other parameters (effective half-time of radioiodine 
excretion in remnants and metastatic lymph nodes, level 
of radioiodine accumulation in them) into analysis does 
not increase the confidence of the model (р = 0.04). 
Thus, treatment outcome does not depend on half-time 
of radioiodine excretion from remnants as well as level of 
radioiodine accumulation in lymph nodes (normal thyroid 
tissue is more radio resistant then lymph nodes [11]). 
To assess the predictive strength of the model pro-
posed, the relationship between f and the real values of 
σ has been plotted for different therapeutic activities.
In Fig. 3 the function f(σ) is represented under the 
assumption that all patients were given the same activ-
ity value (it could be plotted since σ does not correlate 
with activity value) – 
A1 = 5000 MBq;
A2 = 3631 MBq (average value);
A3 =3000 MBq;
A4 =2000 MBq.
From Fig. 3 it could be seen that f > 0.7 at 
A = 5000 MBq. Thus, probability to pass only one course 
is rather high after administration of 5000 MBq. When 
the activity exceeds 5000 MBq, the individual clinical 
features do not appear to affect significantly on the 
outcome of the first course. Activity of 2000 MBq is 
insufficient whatsoever value of σ (f < 0.5). Nevertheless, 
in reality even one course may be sufficient in rather low 
activities approximately 1100 MBq.
With the aim to show the difference in the patterns 
of scintigramm in patients included into analysis three 
patterns of scintigram are given in Fig. 4, 5, 6.
Fig. 3. f(σ) calculated at different activities value A1 = 5000 MBq, 
A2 = 3631 MBq (average value); A3 = 3000 MBq; A4  = 2000 MBq
Fig. 4. Patient N. Follicular thyroid cancer. Thyroid remnants 
and metastases in lymph nodes of the neck are visualized on 
scintigram. The first activity was 3330 MBq 
Patient N, Fig. 4, has undergone one course for 
total thyroid tissue ablation that coincided with the 
calculated value f of the proposed model.
In spite of the significant individual differences in the 
size of remnants, the number and the size of the affect-
ed lymph nodes, as shown in the scintigrams (Fig. 4–6) 
in all the cases the first radioiodine activity turned out to 
be decisive factor for radiotherapy outcome. 
It is interesting to pay attention to the patients who 
were given several courses of the treatment but ac-
cording to the model the total ablation should have 
taken place after the first course (4 patients) and vise 
versa — according to the model patients should have 
gone few courses but total ablation was revealed after 
the first course (2 patients). Thus, the model failed in 6 
patients. 4 patients had follicular cancer, 2 — papillary 
one. No peculiar characteristics have been evident in 
scintigrams of these patients and individual σ values did 
not differ from σav. Uроn analysis of the scintigrams of 
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these patients small remnants volume (σ =3.04 and σ 
= 7.16) and low level of 131I accumulation in pathological 
lymph nodes were revealed in patients after one course 
(2 patients) in the first treatment activities A  = 2364 MBq 
and A = 2368 MBq, while in the cases of the necessity of 
few courses activities were equal  3700 MBq in average 
but parameters of 131I kinetics in remnants varied a little 
from average meanings. Thus, such results could rather 
be referred to individual radiosensitivity.
 
Fig.5. Patient Z. Papillary thyroid cancer. Thyroid remnants 
and metastases in lymph nodes are visualized. 2 courses of 
radioiodine treatment were necessary. 4300 MBq — the first 
therapeutical activity. According to the model total ablation 
should have take place after 1 course
Fig. 6. Patient M. Papillary cancer of thyroid. Thyroid remnants 
and metastases in lymph nodes. First activity was 4500 MBq. 
Patient has undergone 1 course of the treatment which coincided 
with calculations 
disCUssion
Activity value is the only variable parameter that 
could be changed during the treatment. As a rule, in the 
case of metastases in lymph nodes accumulating radio-
iodine the activities amount from 3600 to 7400 MBq [1]. 
There are cases when the volume of thyroid remnants 
after the surgery is large and thus pathological lymph 
nodes are not visualized during scintigraphy. Although 
131I accumulation in metastatic lymph nodes as a rule 
is less then in remnants (as well as Teffective), metastatic 
lymph nodes require less doses for their eradication 
– approximately 80 — 100 Gy as compared with 300 
– 1000 Gy for remnants [12]. The higher radiosensitiv-
ity of the pathological thyroid tissue as compared to 
the normal one [10] may be helpful to explain the data 
cited above.  May be due to the same difference in ra-
diosensitivity, the volume of the remnants has decisive 
influence on the treatment outcome of the first course. 
The model proposed in this study states that the treat-
ment outcome of the first course is determined by the 
first activity value and the level of 131I accumulation in 
remnants but does not depend on Teff in remnants. It 
is possible that predominant part of the dose (whether 
sufficient or not enough for ablation) is absorbed in 
remnants within the first day of the treatment. 
The results of this analysis do not exclude the at-
tempts of the individual approach to the treatment that 
could be useful in understanding the radiobiological 
effects of thyroid tissue ablation and 131I distribution 
in remnants and metastases. Several researches are 
attempting to correlate the first treatment activity of 
radioiodine with the neck uptake in 24 or 48 h after 
administration of the low diagnostic activity (approxi-
mately 74 MBq). Meanwhile, effectiveness of 1100 
MBq of 131I in producing ablation did not correlate 
with 131I uptake by the thyroid remnants, surgeon’s 
estimate of remnant size, or dose delivered to the 
remnant, calculated using reasonable assumptions. 
These findings emphasize the difficulty of dosimetric 
measurements and calculations [4, 9, 14]. It was also 
shown that such factors as age, gender, tumor histol-
ogy, stage, pre–therapy neck uptake of 131I, diagnostic 
dose, TSH — level, ablation dose, time between di-
agnostic and therapeutic dose, etc.  have rather low 
influence on the treatment outcome [7]. Nevertheless 
higher therapeutic activities are associated with higher 
rates of successful ablation, even when administered 
to patients with more advanced cancer. 
Meanwhile, the optimal 131I activity necessary to 
achieve total ablation of remnants and metastases 
remains uncertain [11].
Some authors indicate that to achieve ablation is 
more difficult with increasing individual percentage 
of 131I uptake that confirms our data. Nevertheless, in 
[3] the conclusion has been made that in the percent-
ages of successful ablation, there were no significant 
differences between 131I activities of 3700–5500 MBq, 
5500–6500 MBq, 6600–7300 MBq, and 7400 MBq 
or more. The 3700–5500 MBq ablative activity may 
furnish adjuvant therapy for occult metastases. 
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The results of our study suggest that therapeutical 
activities for treatment of thyroid cancer with metasta-
ses in lymph nodes should be not less then 5000 MBq 
if other restrictions are absent.
Within the activities exceeding 5000 MBq, the 
number and the volume of the affected lymph nodes 
as well as histology of the tumor do not appear to con-
tribute substantially to the outcome of the treatment 
after the first activity administration in patients with 
metastases in lymph nodes. The choice of the activi-
ties exceeding 5000 MBq as well as those inferior to 
this value is rather doubtful. 
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влияние ТеРАПевТиЧеСКОЙ АКТивнОСТи i-131 нА РеЗУлЬТАТ 
РАДиОЙОДОТеРАПии ДиФФеРенЦиРОвАннОГО РАКА 
ЩиТОвиДнОЙ ЖелеЗЫ ПРи меТАСТАТиЧеСКОм ПОРАЖении 
лимФОУЗлОв: мАТемАТиЧеСКАя КОРРеляЦия и 
КлиниЧеСКОе ПРименение
Цель: оценить  влияние первой лечебной активности 131I на результат радиойодотерапии по сравнению с размерами 
остаточной ткани щитовидной железы, количеством и размерами метастазов в лимфоузлах. Материалы и методы: 
68 больным с дифференцированным раком щитовидной железы проводили лечение радиойодом после тиреоидэктомии. У 
всех пациентов было выявлено патологическое накопление 131I в пораженных лимфоузлах. Введенные активности принимали 
значение от 1000 до 6000 МБк. Для полного уничтожения тиреоидной ткани, включая метастатические очаги поражения, 
необходимо было  провести от 1 до 4 курсов радиойодотерапии. Для оценки вероятности полного уничтожения метастазов 
и остаточной ткани после первого курса радиойодотерапии была выбрана логистическая функция. Результаты:  результат 
применения I курса радиойодотерапии  не зависит от уровня накопления 131I в лимфоузлах, а также от эффективного периода 
полувыведения радиойода из остаточной ткани щитовидной железы. Выводы: у больных с дифференцированным раком 
щитовидной железы в случае наличия пораженных лимфоузлов, в  которых накапливается  радиойод, первая лечебная 
активность не должна быть меньше 5000 МБк — для уменьшения количества курсов радиойодотерапии до минимума. 
Результат применения радиойодотерапии слабо зависит от таких факторов, как гистология, а также от количества 
пораженных лимфоузлов и уровня накопления радиойода в них.
Ключевые слова: рак щитовидной железы, метастазы, 131I, кинетика.
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